<main lang="en" role="main" class="html-publication">
      

  <div class="publication-external">
    <ul class="organisation-logos">
        <li class="organisation-logos__logo">
          
<div class="gem-c-organisation-logo brand--department-of-health">
    <a class="gem-c-organisation-logo__container gem-c-organisation-logo__link gem-c-organisation-logo__crest gem-c-organisation-logo__crest--single-identity brand__border-color" href="/government/organisations/department-of-health-and-social-care">
      <span class="gem-c-organisation-logo__name">Department<br>of Health &amp;<br>Social Care</span>
</a>
</div>
        </li>
    </ul>
  </div>

  <header class="gem-c-inverse-header  gem-c-inverse-header--padding-top ">
    
  

<div class="gem-c-title gem-c-title--inverse govuk-!-margin-top-8 govuk-!-margin-bottom-0">
      <span class="govuk-caption-xl gem-c-title__context">
    Guidance
  </span>

  
  <h1 class="gem-c-title__text govuk-heading-xl">
    Technical validation protocol for SARS-CoV-2 nucleic acid detection
  </h1>
</div>
  <p class="publication-header__last-changed">Updated 1 December 2021</p>

  </header>



<div class="govuk-grid-row sidebar-with-body" data-module="sticky-element-container">
    <div class="govuk-grid-column-one-quarter-from-desktop contents-list-container">
        <nav role="navigation" class="gem-c-contents-list" data-module="gem-track-click" aria-label="Contents">
    <h2 class="gem-c-contents-list__title">
      Contents
</h2>
    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-category="contentsClicked" href="#assay-description-and-intended-purpose" class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-label="#assay-description-and-intended-purpose" data-track-options="{&quot;dimension29&quot;:&quot;\n1. Assay description and intended purpose&quot;}" data-track-action="content_item 1"><span class="gem-c-contents-list__number">1. </span><span class="gem-c-contents-list__numbered-text">Assay description and intended purpose</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a href="#type-of-sample-to-be-used-in-validation" data-track-label="#type-of-sample-to-be-used-in-validation" data-track-action="content_item 2" data-track-category="contentsClicked" class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-options="{&quot;dimension29&quot;:&quot;\n2. Type of sample to be used in validation&quot;}"><span class="gem-c-contents-list__number">2. </span><span class="gem-c-contents-list__numbered-text">Type of sample to be used in validation</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-options="{&quot;dimension29&quot;:&quot;\n3. Equipment and reagents&quot;}" href="#equipment-and-reagents" data-track-category="contentsClicked" data-track-action="content_item 3" data-track-label="#equipment-and-reagents" class="gem-c-contents-list__link govuk-link govuk-link--no-underline"><span class="gem-c-contents-list__number">3. </span><span class="gem-c-contents-list__numbered-text">Equipment and reagents</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-category="contentsClicked" data-track-action="content_item 4" data-track-options="{&quot;dimension29&quot;:&quot;\n4. Performance characteristics&quot;}" class="gem-c-contents-list__link govuk-link govuk-link--no-underline" href="#performance-characteristics" data-track-label="#performance-characteristics"><span class="gem-c-contents-list__number">4. </span><span class="gem-c-contents-list__numbered-text">Performance characteristics</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-options="{&quot;dimension29&quot;:&quot;\n5. Precision and robustness&quot;}" data-track-category="contentsClicked" class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-label="#precision-and-robustness" href="#precision-and-robustness" data-track-action="content_item 5"><span class="gem-c-contents-list__number">5. </span><span class="gem-c-contents-list__numbered-text">Precision and robustness</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a href="#analytical-specificity-interferences-and-cross-reactions" data-track-category="contentsClicked" class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-label="#analytical-specificity-interferences-and-cross-reactions" data-track-options="{&quot;dimension29&quot;:&quot;\n6. Analytical specificity (interferences and cross-reactions)&quot;}" data-track-action="content_item 6"><span class="gem-c-contents-list__number">6. </span><span class="gem-c-contents-list__numbered-text">Analytical specificity (interferences and cross-reactions)</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-action="content_item 7" class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-options="{&quot;dimension29&quot;:&quot;\n7. Diagnostic sensitivity and specificity (clinical validation with confirmed positives and negatives)&quot;}" data-track-category="contentsClicked" href="#diagnostic-sensitivity-and-specificity-clinical-validation-with-confirmed-positives-and-negatives" data-track-label="#diagnostic-sensitivity-and-specificity-clinical-validation-with-confirmed-positives-and-negatives"><span class="gem-c-contents-list__number">7. </span><span class="gem-c-contents-list__numbered-text">Diagnostic sensitivity and specificity (clinical validation with confirmed positives and negatives)</span></a>

        </li>
    </ol>
</nav>
      
<div class="gem-c-print-link govuk-!-display-none-print govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button class="govuk-link govuk-body-s gem-c-print-link__button" data-module="print-link">Print this page</button>
</div>
    </div>

  <div class="print-wrapper">
    <div class="print-meta-data">
      <p>
  <img src="/assets/government-frontend/open-government-licence-min-e98134ae65ff5fe99a524d8c383350b3998f91c298dc24b36126e65f1656c578.png" class="print-meta-data-licence">
</p>
<p>
  © Crown copyright 2021
</p>
<p>
  This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit <a href="https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3">nationalarchives.gov.uk/doc/open-government-licence/version/3</a> or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: <a href="mailto:psi@nationalarchives.gov.uk">psi@nationalarchives.gov.uk</a>.
</p>
<p>
  Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
</p>
<p>
  This publication is available at https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/technical-validation-protocol-for-sars-cov-2-nucleic-acid-detection
</p>


    </div>
  </div>

  <div class="main-content-container">
    <div class="gem-c-govspeak-html-publication">
  
<div class="gem-c-govspeak govuk-govspeak " data-module="govspeak">
    
    
      <div class="govspeak">
<h2>
<span class="number">1. </span>Assay description and intended purpose</h2>

<p>1.1	What is the principle and method of the assay (description of the assay according to the manufacturer’s instructions for use (<abbr title="instructions for use">IFU</abbr>)?</p>

<p>1.2	What is the use for which the device is intended according to the data supplied by the manufacturer on the label, in the <abbr title="instructions for use">IFU</abbr>, in promotional or sales materials or statements, or as specified by the manufacturer in the performance evaluation?</p>

<p>1.3	Is the test a stand-alone device/test or to be used in conjunction with other equipment and is biosafety containment is required?</p>

<h2>
<span class="number">2. </span>Type of sample to be used in validation</h2>

<p>2.1	Stipulate the sample type (for example whole non-extracted virus, extracted RNA, synthetic RNA, plasmid DNA containing assay target regions) and any sample matrices (for example saliva, plasma, nasopharyngeal/oronasal swab [dry or in VTM] and so on) in which the material is to be spiked.</p>

<p>2.2	Stipulate if the material is required to be extracted: that is volume received, volume extracted, volume eluted, elution buffer to be used in the assay.</p>

<p>2.3	If possible, stipulate if any interfering substances such as preservatives are likely to be present. Shelf life and number of freeze thaw events should also be stated, if known. Where dry swabs are to be used, samples will need to be collected prospectively; 2 swabs per participant, one for a new test and one to be tested using reference method; or one swab for a new test collected within 24 hours of a positive reference method swab.</p>

<h2>
<span class="number">3. </span>Equipment and reagents</h2>

<p>3.1	List all the equipment required that are not supplied by the manufacturer with calibration/service requirements and dates where applicable.</p>

<p>3.2	List all the reagents required that are not provided by the manufacturer with shelf-life expiry dates and storage conditions. Include positive and negative control materials.</p>

<h2>
<span class="number">4. </span>Performance characteristics</h2>

<p>4.1	Analytical sensitivity and linearity of SARS COV-2 targets</p>

<p>4.1.1	Dilution series: this should be calculated using a validated standard dilution series. If this is not possible (as standard material is not available), use 5 clinical positive replicates, with a 5 log10 dilution, plus 5 negatives, plus the use of inhibition controls. If feasible, repeat over several days, different users/machines (feasibility may be limited due to availability of positive material). Where dry swabs are to be used, known amounts of standard material should be added to the swab, and then tested as per <abbr title="instructions for use">IFU</abbr>. Reference to be made on the reporting of results and for example CT values.</p>

<p>4.1.2	Linearity and efficiency: Ideally for linearity, the use of a standardised reference panel should be used to ensure effective benchmarking and assure that dilutions are accurate. If an alternative route for establishing linearity is undertaken, the method will need to be documented For LAMP assays the linearity will need to be standardised via dilutions in appropriate matrixes using untreated virus. Plot the data from 4.1.1 and calculate linearity and efficiency. Compare the data with that supplied by the manufacturer, if applicable.</p>

<p>4.1.3	Lowest Limits of Detection (<abbr title="Lowest Limits of Detection">LLOD</abbr>): Where a validated standard dilution series was used <abbr title="Lowest Limits of Detection">LLOD</abbr> should be calculated, using data from 4.1.2, in copies/ml (to align with the relevant MHRA).TPP). Where clinical positive material is used, copies/ml cannot be calculated; median CT value or dPCR should be given for the lowest dilution detected from the samples used in 4.1.1.</p>

<h2>
<span class="number">5. </span>Precision and robustness</h2>

<p>5.1	Intra-assay precision: Use the data for 5 replicate values from a single day from 4.1.1 to calculate Standard Deviation &amp; Coefficient of Variation measurement, with the values for the latter to be &lt;10%. To include the use of inhibition controls.</p>

<p>5.2	Inter-assay precision: Use the data for 5 replicate values from multiple days from 4.1.1 for Standard Deviation &amp; Coefficient of Variation with the values for the latter to be &lt;15%.</p>

<p>5.3	Repeatability: Spike 30 negative samples from different individuals with known amount of agent/positive material (suggested 3x the <abbr title="Lowest Limits of Detection">LLOD</abbr>), all should be positive.</p>

<h2>
<span class="number">6. </span>Analytical specificity (interferences and cross-reactions)</h2>

<p>6.1	Cross-reactivity to non-target samples/organisms. A range of samples either direct clinical samples or spiked samples that are known positives for other diseases, both closely related (such as other coronaviruses), syndromic diseases (such as other respiratory viruses and bacteria) and common diseases (such as HIV, HBV, HCV, VZV, EBV, CMV) should be tested.</p>

<h2>
<span class="number">7. </span>Diagnostic sensitivity and specificity (clinical validation with confirmed positives and negatives)</h2>

<p>7.1	Samples selected for this validation will be appropriate to the assay. Low medium and high viral load samples will be be equally distributed to avoid increasing or lowering DSe and DSp.</p>

<p>7.2	Diagnostic sensitivity: Confirmed clinical samples from patients (positive RT-qPCR result) should be used. Preferably, depending on the availability of samples, ~150 samples should be included to align with MHRA TPP.  Clinical sensitivity (95% <abbr title="confidence interval">CI</abbr>) and positive predictive value (PPV) should be calculated in comparison with a CE marked reference method that itself has sensitivity and specificity and a limit of detection within the specifications of the MHRA TPP. The CT values or equivalent for both the assessed and comparator assays must be included in the validation report.</p>

<p>7.3	Diagnostic specificity: Confirmed clinical samples from patients (negative RT-qPCR result) should be used. Preferably, depending on the availability of samples, ~250 samples should be included to align with MHRA TPP.  Clinical specificity (95% <abbr title="confidence interval">CI</abbr>) and negative predictive value (PPV) should be calculated in comparison with a CE marked reference method that itself has sensitivity and specificity in line with the MHRA TPP. The CT values or equivalent for both the assessed and comparator assays must be included in the validation report.</p>

</div>


</div>
</div>
  </div>

  <div class="sticky-element" data-sticky-element="">
    <a href="#contents" class="govuk-link app-c-back-to-top dont-print">
    <svg width="13" height="17" xmlns="http://www.w3.org/2000/svg" class="app-c-back-to-top__icon" viewBox="0 0 13 17" focusable="false">
      <path d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z" fill="currentColor"></path>
    </svg>
    Contents
</a>

    <div class="sticky-element__print-link">
      
<div class="gem-c-print-link govuk-!-display-none-print govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button class="govuk-link govuk-body-s gem-c-print-link__button" data-module="print-link">Print this page</button>
</div>
    </div>
  </div>
</div>

    </main>